Market Overview:
The market for autologous cell therapy worldwide was worth USD 5.90 billion in 2022 and is projected to rich USD 34.31 Billion by 2033, growing at a compound annual growth rate (CAGR) of 19.4% from 2023 to 2033. Several factors contribute to the growth of this market, including various immunological benefits, an increasing global population of elderly individuals, and a decreased risk of rejection in autologous cell therapy.
Autologous cell therapy, also known as autologous cellular immunotherapy, is a ground-breaking approach in the field of regenerative medicine. It involves harvesting cells from an individual's own body, processing and modifying them in a laboratory setting, and then reintroducing them back into the same person for therapeutic purposes. This personalized treatment approach aims to harness the inherent healing potential of a patient's cells to treat various diseases and conditions.
Autologous cell therapy uses the patient's own cells, eliminating the risk of rejection or adverse immune reactions. Since the cells are derived from the patient's own body, there is no need for immunosuppressive drugs, which are often required in allogeneic cell therapies. Autologous cell therapy is personalized medicine at its core. It allows for individualized treatment tailored to the specific needs of each patient. By using the patient's own cells, therapies can be customized to address their unique genetic makeup, disease characteristics, and medical history.
Autologous cell therapy has demonstrated long-term efficacy in various medical fields. For example, in the field of regenerative medicine, autologous stem cell therapies have shown promising results in promoting tissue repair and regeneration. The use of the patient's own cells enhances the potential for successful integration and long-term therapeutic effects.
Report Attributes | Description |
Market forecast in 2022 | USD 5.90 billion |
Market forecast in 2033 | USD 34.31 billion |
CAGR% 2023-2033 | 19.4 % |
Base year | 2022 |
Historic data | 2020-2021 |
Forecast period | 2023-2033 |
Report USP | Product, End User, company share, company heat map, company capacity, technology, product capacity, growth factors and more |
Key Companies | BrainStorm Cell Therapeutics; Holostem Terapie Avanzate S.R.L; Pharmicell Co. Inc; Opexa Therapeutics; Caladrius Biosciences Inc; U.S. Stem Cell Inc; Lonza; Bristol Myers Squibb; Novartis; Autolus therapeutics; Tego Science; Others |
Global Autologous Cell Therapy Market: KeyTrends• Advancements in technology: Technological advancements, such as improved cell isolation and expansion techniques, have played a crucial role in the development and progress of autologous cell therapies. Innovative technologies like gene editing, induced pluripotent stem cells (iPSCs), and tissue engineering are enhancing the therapeutic potential and expanding the scope of autologous cell therapies.
• Increasing clinical applications: Autologous cell therapy is finding applications across various therapeutic areas. It is being explored for the treatment of conditions like cancer, cardiovascular diseases, neurodegenerative disorders, autoimmune diseases, orthopedic injuries, and wound healing, among others. The widening range of clinical applications is driving the growth and adoption of autologous cell therapies.
Global Autologous Cell Therapy Market: Regional analysis
North America:
North America, particularly the United States, holds a significant share in the autologous cell therapy market. The region has a well-established healthcare infrastructure, advanced research facilities, and a favourable regulatory environment. The presence of key market players, increased funding for research and development, and a strong focus on regenerative medicine contribute to the growth of the autologous cell therapy market in this region.
Europe:
Europe is another prominent market for autologous cell therapy. Countries such as Germany, the United Kingdom, France, and Switzerland have a strong presence in the field of regenerative medicine and cell therapy research. The region benefits from supportive government initiatives, a robust healthcare system, and collaborations between academic institutions, research organizations, and industry players. The European Medicines Agency (EMA) plays a vital role in regulating and approving cell therapies, providing a clear pathway for market entry.
Asia Pacific:
The Asia Pacific region is witnessing rapid growth in the autologous cell therapy market. Countries like Japan, China, South Korea, and Australia are investing heavily in regenerative medicine research and development. The region boasts a large patient population, a rising prevalence of chronic diseases, and a growing demand for advanced healthcare solutions. Moreover, favourable government policies, increased funding, and the presence of key market players are driving the growth of the autologous cell therapy market in Asia Pacific.
Global Autologous Cell Therapy Market: Segmentation
Autologous Cell Therapy Market source outlook:
• Epidermis
• Mesenchymal stem cells
• Haematopoietic stem cells
• Chondrocytes
• Others
Autologous Cell Therapy Market Application Outlook:
• Cancer
• Neurodegenerative disorders
• Cardiovascular disorders
• Autoimmune disorders
• Orthopedics
• Wound healing
• Others
Autologous Cell Therapy Market End-Use Outlook:
• Hospitals & Clinics
• Ambulatory Centers
• Academics & Research
• Others
Global Autologous Cell Therapy Market: Recent Development
On June 23, 2021 Switzerland-based Lonza Group Ltd. and Canada-based Octane Biotech Inc. have recently announced their partnership to conduct an exclusive assessment of Octane Biotech's innovative cell production platform, known as the Octane Cocoon™. The purpose of this collaboration is to evaluate the technology for personalized cell therapy manufacturing, with the ultimate objective of implementing this ground-breaking innovation on a global scale.
Global Autologous Cell Therapy Market: Impact of covid-19
• Disruption in clinical trials: The pandemic has caused significant disruptions in ongoing clinical trials for autologous cell therapies. Many trials were temporarily halted or delayed due to restrictions on patient recruitment, limitations on hospital resources, and prioritization of COVID-19-related research. This disruption has slowed down the progress of clinical development and delayed the commercialization of some therapies.
• Supply chain challenges: The autologous cell therapy market relies on a complex supply chain, including the collection, processing, and delivery of patient-specific cells. The pandemic has posed challenges to the supply chain, including disruptions in the availability of critical reagents, laboratory closures, and limitations on the transportation of cellular products. These challenges have impacted the manufacturing and delivery timelines for autologous cell therapies.
• Increased focus on regenerative medicine: The COVID-19 pandemic has heightened the focus on regenerative medicine, including autologous cell therapies. The pandemic has highlighted the importance of innovative and advanced medical treatments, leading to increased investments in research and development of regenerative therapies. This increased focus and investment may have long-term positive effects on the autologous cell therapy market.
Global Autologous Cell Therapy Market: Company Profiles
• BrainStorm Cell Therapeutics
• Holostem Terapie Avanzate S.R.L
• Pharmicell Co. Inc
• Opexa Therapeutics
• Caladrius Biosciences Inc
• U.S. Stem Cell Inc
• Lonza
• Bristol Myers Squibb
• Novartis
• Autolus therapeutics
• Tego Science
• Others
Global Autologous Cell Therapy Market: Regional Scope
North America
• U.S
• Canada
• Mexico
Europe
• U.K
• Germany
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific
• Chain
• India
• Japan
• South Korea
• Australia
• Rest of Asia pacific
South America
• Brazil
• Argentina
• Rest of south America
Middle East and Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of Middle East and Africa
Why to buy this Report?
• Market research: The report provides valuable insights into market trends, growth opportunities, and competitive landscapes. By reading a technology report, businesses and investors can gain a better understanding of the market they are operating in or considering entering, and make more informed decisions based on data and analysis.
• Competitive analysis: The report reports provide detailed information on competitors' strengths, weaknesses, and strategies, which can help businesses identify potential threats and opportunities in the market.
• Innovation: The report provides insights into emerging technologies and trends, which can help businesses stay up-to-date with the latest developments and make informed decisions about where to invest their resources.
• Due diligence: The report can be used by investors and acquirers as part of their due diligence process when considering investing in or acquiring a technology company. These reports can provide valuable information on the company's financials, technology, market position, and other key factors.
Frequently Asked Questions
• What is the market size and growth projections?
• What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?
• What are the top performing segments, and countries / regions of each of the markets?
• What is the market size and growth rate across key countries / regions?
• How big is the global & regional market in terms of revenue and volume?
• How far market will grow in forecast period in terms of revenue and volume?
• What factors will influence demand and supply trends across each markets during the forecast period?
• What are the technology trends shaping various markets?
• Which country / region has more opportunities?
• What is the COVID-19 impact on the market and how long will it take to recover?
• Who are the key competitors of market Players?
• What are the market share (%) of Key Players?
• What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?
• What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?